These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32326676)

  • 1. Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice.
    Cakal B; Cakal S; Karaca O; Omaygenc MO; Yilmaz FK; Gunes HM; Ozcan OU; Ibisoglu E; Boztosun B
    Minerva Cardiol Angiol; 2021 Jun; 69(3):261-268. PubMed ID: 32326676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year outcome of everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stents: a comprehensive updated meta-analysis of randomized controlled trials.
    Zhang H; Zhao J; Xu Y; Zhang W; Sui Y; Liu Q; Wang Y; Liu Z; Gao R; Wu Y
    Expert Rev Med Devices; 2019 May; 16(5):421-427. PubMed ID: 31008654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter post-marketing evaluation of the Elixir DESolve
    Nef H; Wiebe J; Boeder N; Dörr O; Bauer T; Hauptmann KE; Latib A; Colombo A; Fischer D; Rudolph T; Foin N; Richardt G; Hamm C
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1021-1027. PubMed ID: 29508518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study.
    Brugaletta S; Gori T; Tousek P; Gomez-Lara J; Pinar E; Ortega-Paz L; Schulz E; Kocka V; Münzel T; Cequier À; Buono A; Serruys PW; Sabaté M;
    EuroIntervention; 2020 Mar; 15(16):1436-1443. PubMed ID: 31845896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
    Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A
    Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Full-plastic jacket" with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413).
    Tarantini G; Masiero G; Fovino LN; Mojoli M; Varricchio A; Loi B; Gistri R; Misuraca L; Gabrielli G; Cortese B; Pisano F; Moretti L; Tumminello G; Olivari Z; Mazzarotto P; Colombo A; Calabrò P; Nicolino A; Tellaroli P; Corrado D; Durante A; Steffenino G;
    Int J Cardiol; 2018 Sep; 266():67-74. PubMed ID: 29887475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry.
    Imori Y; D'Ascenzo F; Gori T; Münzel T; Fabrizio U; Campo G; Cerrato E; Napp LC; Iannaccone M; Ghadri JR; Kazemian E; Binder RK; Jaguszewski M; Csordas A; Capasso P; Biscaglia S; Conrotto F; Varbella F; Garbo R; Gaita F; Erne P; Lüscher TF; Moretti C; Frangieh AH; Templin C
    Cardiol J; 2016; 23(4):374-83. PubMed ID: 27515481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
    Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS.
    Hommels TM; Hermanides RS; Berta B; Fabris E; De Luca G; Ploumen EH; von Birgelen C; Kedhi E
    Cardiovasc Diabetol; 2020 Oct; 19(1):165. PubMed ID: 33008407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.